Nasus Pharma Ltd., a clinical-stage specialty pharmaceutical company focused on the development of intranasal drugs to treat emergency medical conditions. It offers Powder-Based Intranasal (PBI) products to address acute medical conditions and public health threats. The company's products include NS002, Intranasal Epinephrine for assisting in severe allergic reaction emergency situations and NS001, an Intranasal Naloxone powder nasal spray for the treatment of opioid overdose. Nasus Pharma Ltd. was incorporated in 2019 and is based in Tel Aviv-Yafo, Israel.
Frequently asked questions
What sector does Nasus Pharma Ltd. (NSRX) operate in?
Nasus Pharma Ltd. belongs to the Healthcare sector and operates in the Drug Manufacturers - General industry.
What is Nasus Pharma Ltd. (NSRX) current stock price?
As of the latest data, Nasus Pharma Ltd. stock price is $3.49, with a previous close of $3.49.
What is Nasus Pharma Ltd. (NSRX) current market capitalization?
Nasus Pharma Ltd. market cap is approximately 40.88 million.
What is Nasus Pharma Ltd. (NSRX) Earnings Per Share (EPS)?
The trailing EPS is -$1.13, and the forward EPS is -$1.13.
What is Nasus Pharma Ltd. (NSRX) EBITDA?
Nasus Pharma Ltd. EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -5.95 million.
Does Nasus Pharma Ltd. (NSRX) pay dividends?
No. Nasus Pharma Ltd. does not pay a dividend.
What is Nasus Pharma Ltd. (NSRX) beta (volatility) score?
Nasus Pharma Ltd. has a beta of 0.275, indicating lower volatility than the overall market.